Conditionally replicating adenoviruses (CRAd) 'armed' with prodrug-activating genes have the potential to augment the efficacy of virotherapy. An Escherichia coli nitroreductase (NTR) gene (nfsB) 
Introduction
Gene therapeutics are likely adjuncts in future cancer treatment. 1, 2 The therapeutic index of replication-competent viral vectors can, in principle, exceed conventional therapies by virtue of their capacity for unlimited amplification in tumors with attendant cytolysis. [3] [4] [5] [6] Conditionally replicating adenovirus (CRAd) of serotype 5 is a widely evaluated replicating virus platform [7] [8] [9] primarily because the genetic basis of lifecycle regulation is understood, [10] [11] [12] readily manipulated and amenable to high titer production. 13, 14 Onyx Pharmaceuticals Inc. developed the first CRAd, an E1B-55k-deleted oncolytic adenovirus ONYX-015 (dl1520), 15 the clinical safety and therapeutic potential of which has been demonstrated in combination with systemic chemotherapy. 16, 17 Onyx subsequently generated a CRAd harboring a partial deletion of the E1A CR2 domain (dl922-947) 18 and showed this to suppress E1A/pRb complex formation necessary for cell-cycle progression, restricting oncolytic activity to neoplastic cells lacking G 1 -S-phase checkpoint control. Modification of dl922-947 to incorporate E2F1-regulation of E1A DCR2 and E4 genes resulted in ONYX-411, 19 a CRAd which displayed potent cytolytic activity against cancer cells but was essentially replication deficient in primary cultured cell lines. This genomic configuration exploits both deregulation of the pRb pathway (p16-cyclinD1/Cdk4-pRb) 20, 21 and obligatory availability of E2F-1, 22 ,23 molecular aberrations that typify the neoplastic state. [24] [25] [26] [27] This selectivity provides systemic intravenous (IV) antitumor activity in experimental xenograft models 19, 28 identifying it as a suitable vector platform for virotherapy of cancer.
The antitumor efficacy of CRAds can be improved through the introduction of additional potency-enhancing genes. [29] [30] [31] Prodrug-activating genes ('suicide genes') are attractive candidates for 'arming' CRAds since augmentation of viral activity is conditional on prodrug administration, thereby allaying biosafety concerns associated with directly toxic gene products. 32 This approach, termed virus-directed enzyme-prodrug therapy (VDEPT), utilizes deactivated precursors of cytotoxic agents that require metabolism to exert their antiproliferative effects. 33, 34 The most clinical advanced enzyme/prodrug combinations for VDEPT are Escherichia coli cytosine deaminase (CD) for conversion of 5-fluorocytosine to the antineoplastic agent 5-fluorouracil, and herpes simplex virus thymidine kinase (TK) for activation of the prodrug gancyclovir. 35 CD and TK-armed E1B-deleted CRAds have prodrug enhanced efficacy in vivo. [36] [37] [38] [39] Onyx Pharmaceuticals engineered both ONYX-015 and ONYX-411 to express CD from the E3B region and have shown the latter to be superior 28 ; ONYX-411 CD provided a selective and progressive rise in tumor xenograft CD activity over a 21-day period following IV administration, whereas ONYX-015 CD gave declining enzyme activity with time. ONYX-411 is therefore a vector platform capable of systemic transgene delivery to human tumor xenografts.
A range of prodrug activating genes and their prodrugs have been developed to catalytically unmask various DNA-interactive antimetabolite, intercalator, alkylator and free-radical-generating effectors. 35, 40, 41 Among the more promising is E. coli nitroreductase (NTR; product of the nfsB gene) which can reduce nitro(hetero)aromatic compounds to the corresponding hydroxylamines and amines, a chemical transformation that can function as a powerful 'electronic switch'. 42, 43 The prototype NTR prodrug CB 1954 (5-aziridinyl-2,4-dinitrobenzamide) is metabolized by NfsB to DNA reactive products that act as cell cycle independent cytotoxins 44 and which can provide a bystander effect as a result of diffusion from NTR-expressing cells. 45, 46 Efficacy has been demonstrated in low density cell culture models [47] [48] [49] [50] [51] [52] and against tumor xenografts using replication-defective viruses. [52] [53] [54] [55] Phase I trials of CB 1954, alone 56 and in conjunction with a non-replicating NTR-armed adenovirus have been conducted. 57, 58 However, CB 1954 has poor formulation characteristics 56 that have not been overcome by analog development 59, 60 and a limited bystander effect in 3D cell culture models and xenografts. 46, 61, 62 Of critical importance, CB 1954 provides disappointing plasma concentrations in humans (5.8 mmol h l À1 ) 56 relative to mice (320 mmol h l À1 ) 63 because of dose-limiting hepatotoxicity and diarrhea. 64 Thus, there is a clear requirement for improved NTR prodrugs which has spurred efforts in this area. [65] [66] [67] [68] [69] Here, we report a novel NTR prodrug, the 3,5-dinitrobenzamide-2-bromomustard, SN 27686, and its water-soluble 'pre-prodrug' SN 28343. The prototype of this class, the 2,4-dinitrobenzamide-chloromustard SN 23862 is a better NTR substrate than CB 1954, and provides a more efficient bystander effect, but lacks aqueous solubility and potency. 46, 70 SN 28343 overcomes these limitations. In the present study, we insert NTR into the E3B region of ONYX-411, under viral transcriptional control, and use a novel NTR substrate (SN 29884) as a fluorescent probe to demonstrate expression of NTR with late kinetics (dependent on viral replication) in tumor cell cultures. We also demonstrate progressive amplification of the armed virus (ONYX-411 NTR ) following systemic administration, and enhancement of its therapeutic activity by SN 28343 in H1299 NSCLC xenografts.
Materials and methods

ONYX-411
NTR construction, purification and propagation Seed stock of ONYX-411 and plasmids required for recombinant viral manufacture were provided by Onyx Pharmaceuticals. To create Onyx-411 NTR the minor aerobic NTR NfsB gene from E. coli was polymerase chain reaction (PCR) amplified and ligated into plasmid pE3SV þ V (pGem5ZF þ containing the genomic region 27082-31089 of Adenovirus type 5 (Ac. NC_001405)) harboring unique Cla I/Swa I sites, juxtaposing the E3B region as described. 71 Sequence integrity was confirmed and a 4 kb EcoRI/NdeI fragment containing the E3B-inserted NTR was introduced into the 411 shuttle plasmid, L28-309 (wt-E2F1P) as previously described. 61 and were maintained by passage under puromycin selection (3 mM).
Fluorogenic probe for nitroreductase activity determination To facilitate real time monitoring of whole-cell NTR activity, an in-house library of 123 nitro(hetero)cyclic compounds was screened to identify potential substrates that would yield fluorescent products upon reduction. The cell-permeable probe 1-methyl-6-nitro-4(1H)-quinolinone (SN 29884; see Figure 2a ), an intermediate in the synthesis of the 4-alkylamino nitroquinolines, 72 was identified as a non-fluorescent compound that was reduced efficiently by NTR to provide a highly fluorescent amine product (Ex/Em 355/460). This NTR probe was found to be suitable for low cell density quantification of intracellular NTR activity. To monitor ONYX-411 NTR infection, cells were seeded at 5 Â 10 3 cells per well in 96-well plates, allowed to attach for 4 h and infected with ONYX-411 NTR at various PFU per cell ratios (multiplicity of infection (MOI)). At indicated times postinfection, samples were incubated with SN 29884 by addition of a 50 mM stock solution in dimethyl sulfoxide (DMSO) to a final concentration of 300 mM at 37 1C for 2 h. The reaction was terminated by addition of an equivalent volume of MeOH and read on a fluorescence plate reader at an excitation wavelength of 355 nm with emission at 460 nm (Wallac 1420 Victor multilabel counter; PerkinElmer, Wellesley, MA, USA). For correlation with western blot samples, NTR activity was measured by incubating cultures with SN 29884 (100 mM) for 1 h and sampling directly from the culture medium prior to cell harvest. For viral inhibition studies cytosine arabinoside (ara-C; Sigma-Aldrich) was dissolved in water and added directly to wells (final concentration 20 mg ml
À1
) immediately post-infection at the indicated concentration, as previously reported. 73 
Western immunoblotting
For in vitro studies, 7.5 Â 10 5 cells were infected with ONYX-411 WT or ONYX-411 NTR at MOI 3. At various times, cells were lysed in situ in 50 mM Tris-HCl pH 8 containing 150 mM NaCl, 1 mM EDTA, 1% (v/v) Nonidet P40 (Roche, Indianapolis, IN, USA), 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1% protease inhibitor cocktail (Sigma-Aldrich) and 5% b-mercaptoethanol. Samples were agitated (10 min; 70 1C) and subsequently freeze-thawed three times. Cell debris was removed by centrifugation (1000 g, 2 min) and extracted protein was quantified using the bicinchoninic acid assay 74 (Pierce, Rockford, IL, USA) with bovine serum albumin as reference. Soluble proteins were fractionated by denaturing polyacrylamide gel electrophoresis (PAGE), transferred onto nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) and blocked in PBS containing 5% non-fat dry milk and 0.05% Tween-20 (Serva Electrophoresis, Heidelberg, Germany). Blots were incubated with the following antibodies diluted in blocking solution; mouse anti-fiber diluted 1:25 000 for in vitro blots or 1:15 000 for in vivo blots (Lab Vision, Fremont, CA, USA), mouse anti-b-actin diluted 1:25 000 for in vitro blots or 1:30 000 for in vivo blots (Chemicon, Tenecula, CA, USA) or a sheep anti-NTR serum diluted at 1:10 000. The sheep anti-NTR serum was raised against purified NTR (purchased from CAMR, Porton Down, UK) by immunization with 2 mg protein in Freund's adjuvant, rechallenge with 1 mg every 4 weeks and collection of sera at 10 weeks (South Pacific Sera, Timaru, New Zealand). Signals were detected with horseradish peroxidase-conjugated secondary antibodies diluted 1:20 000 (Zymed, San Francisco, CA, USA) and enhanced chemiluminescence (Pierce). Purified E. coli NTR was loaded as a positive control. Images were acquired using an ImageReader LAS-3000 (Fujifilm, Tokyo, Japan). For in vivo tissues, tumor and liver samples were excised and snap frozen. Tissues were cryopulverized (model 59012MS; BioSpec Products, Bartlesville, OK, USA), and dissolved in five volumes (w/v) 20 mM Tris-HCl (pH 6.8) containing 5 mM EDTA, 0.5 mM DTT, 2% SDS and 1% protease inhibitor cocktail and processed as above.
MOI 50 assay
Cells were seeded at 5 Â 10 3 cells per well in 96-well plates and infected with ONYX-411 WT or ONYX-411 NTR . Cultures were grown for 4 days before fixing with 10% (v/v) TCA and staining with Sulforhodamine B. The MOI 50 was determined by interpolation as the MOI required to reduce staining to 50% of controls on the same plate.
IC 50 assay
The concentration of prodrug required for 50% inhibition of cell growth, following a 4 h exposure and 5 days regrowth, was determined as described. 59, 75 Bystander effect assay Multicellular layers (MCLs) were grown as previously reported. 46, 76 Briefly, 1 Â 10 6 cells consisting of 100% targets (HCT116-WT) or 1% activators (HCT116-NTR puro ) with 99% targets (co-cultures) mixture were grown for 3 days (total cells per MCL 5.470.32 Â 10 6 , mean and s.d.) and exposed to prodrug at various concentrations for 5 h under 95% O 2 /5% CO 2 . To discriminate clonogenic activator (HCT116-NTR puro ) from target (HCT116-WT) cells, trypsinized single cell suspensions were plated (up to 10 5 cells/60 mm dish) in non-selective medium (total cells) or in medium containing 3 mM puromycin (activators only). Colonies were grown for 10 days and stained with methylene blue (0.2% in 50% ethanol). Colonies containing 450 cells were scored and the drug concentration for 10% survival (C 10 ) relative to non-drug-treated controls was calculated by interpolation. Bystander effect efficiency (BEE) was calculated as previously described 46 
Immunohistochemistry
Tumor tissue was excised and fixed in 10% neutralbuffered formalin for 48 h, transferred to 70% ethanol and embedded in paraffin. Sections (4 mm) were cut, mounted onto poly-L-lysine-coated glass slides and heat fixed for 1 h at 60 1C. Sections were dewaxed, rehydrated, washed in distilled water and then rinsed in 0.01 M Trisbuffered saline (TBS, pH 7.4). Antigen retrieval was achieved by boiling samples in 10 mM sodium citrate buffer pH 6 for 25 min. Sections were washed with TBS containing 0.1% Tween-20 (TBS-T) and blocked with 1% goat serum in TBS. After rinsing, the samples were incubated for 1 h at room temperature with anti-fiber diluted 1:200 in PBS containing 0.2% Tween-20. After rinsing in TBS-T slides were incubated with Alexa Fluor 488 goat anti-mouse F(ab') 2 (Molecular Probes, Eugene, OR, USA) at the same dilution, rinsed and mounted with Prolong Gold antifade (Molecular Probes). Serial sections were stained with hematoxylin and eosin. Microscopy (Eclipse TE2000-E; Nikon, Tokyo, Japan) was carried out using a computer-controlled automatic stage (Proscan II; Prior, Rockland, MA, USA) and NIS Elements image acquisition software (Nikon).
Nitroreductase prodrugs
The prodrugs CB 1954, SN 27686 and its phosphate preprodrug, SN 28343, were synthesized as described, 77 
Animal husbandry
Specific pathogen-free homozygous CD-1-Foxn1 nu mice (Charles River Laboratories, Wilmington, MA, USA) and Rag-1 null mice (C.129S7(B6)-Rag1 tm1Mom /J; Jackson Laboratories, Bar Harbor, MA, USA) were bred by the Animal Resources Unit (University of Auckland) and supplied at 7-9 weeks of age. Mice were housed in groups of 4-7 in microisolator cages in a temperature-controlled room (2272 1C) with a 12 h light/dark cycle and were fed ad libitum water and a standard rodent diet (Harlan Teklad diet 2018i). All animals were uniquely identifiable by ear tag number. All animal protocols were approved by the University of Auckland Animal Ethics Committee.
Plasma pharmacokinetics of SN 28343
Three female mice CD-1-Foxn1 nu were dosed with SN 28343 (562 mmol kg À1 ) intraperitoneally (IP). Serial blood samples (20 ml) were collected in heparinized hematocrit tubes by incision of a lateral tail vein, chilled, centrifuged (3000 g for 3 min) and plasma was stored at À80 1C. Thawed plasma was deproteinized with three volumes MeOH, centrifuged at 13 000 g for 5 min, and 35 ml diluted with 75 ml ammonium formate buffer (45 mM, pH 4.5). A total of 100 ml samples were analyzed by HPLC using an Agilent 1100 (Agilent Technologies, Walbronn, Germany) with photodiode array detector. Separation was performed on an Alltima C8 column (150 Â 2.1 mm I.D., 5 mm particle size; Alltech, Chicago, IL, USA) with a flow rate of 0.3 ml min À1 at 25 1C. The mobile phase was a gradient of acetonitrile-water (80:20, v/v) and 45 mM ammonium formate buffer in water (pH 4.5). Calibration curves were constructed by spiking analytes into plasma. Non-compartmental pharmacokinetic parameters were estimated using WINNONLIN version 4.0.1; area under the curve (AUC) values were calculated by extrapolating the C-T curve to infinite time.
Antitumor efficacy
Tumor cells for inoculation of immunodeficient mice were bulked up in vitro, harvested, suspended in serum-free aMEM and implanted subcutaneously. For WiDr colon carcinoma xenografts, 4.5 Â 10 6 WiDr-WT cells were mixed with 0.5 Â 10 6 WiDr-NTR neo cells and implanted in Rag-1 null mice; for C33A cervical carcinoma xenografts 10 7 cells were implanted in Rag-1 null mice. 10 7 H1299 lung carcinoma cells were implanted into CD-1-Fox1 nu nude mice. Tumor-bearing mice were assigned randomly across treatment groups when tumor diameter reached treatment size. Treatment administration began on the day of assignment, after which tumor size and body weights were measured regularly. Animals were culled when the average diameter of the tumor exceeded 15 mm (survival end point) or body weight loss exceeded 15% of pretreatment value. Kaplan-Meier plots were constructed and median time to end point (TTE 50 ) was calculated. The statistical significance of any differences in overall survival between treatment groups and control was analyzed by the Log-rank P-test using SigmaStat v3.1.
Results
Comparative oncolytic activity of ONYX-411
WT and ONYX-411 NTR Introduction of the 808 base pair fragment encoding E. coli nfsB into the E3B region of ONYX-411 (14.5/14.7 K location in Ad5wt) did not measurably modify viral production characteristics. Both viruses provided similar production titers in A549 cultures ranging from 2.1 to 7.5 Â 10 12 plaque forming units per ml (PFU ml
À1
) with particle/PFU ratios from 31 to 49. To compare the oncolytic capacity of ONYX-411
WT and ONYX-411 NTR the MOI 50 was determined across a panel of 11 neoplastic cell lines using a 4-day continuous exposure (Figure 1a) . No significant differences in oncolytic potency were noted between the two viruses for any cell line suggesting that neither introduction of the NTR open-reading frame into the ONYX-411 genome nor expression of NTR protein had influence on ONYX-411 efficacy in vitro. To confirm equivalence in vivo, the maximum tolerated dose (MTD; 100 ml, IV) was determined to be 4 Â 10 9 PFU per mouse for each virus (non-tumor-bearing CD-1 nude mice). Doses in excess of MTD were associated with acute lethality (o1 h), accompanied by tremor and evidence of marked pinna vasodilation. Both viruses were well tolerated at 1 Â 10 9 PFU per mouse. The antitumor activity of both CRAds was assessed by single IV dose of 10 8 PFU in mice bearing established C33A xenografts (140739 mm readily measurable as early as day 1 with sustained activity that decayed slowly beyond day 3. Lowering the initial MOI delayed the peak of NTR presentation. To establish the cell line dependence of NTR expression kinetics and amplitude following ONYX-411 NTR infection, a panel of 11 neoplastic and two primary cell lines were exposed at MOI 3 (Figure 2c) . A range of expression patterns were observed across the neoplastic cell lines with a p9-fold difference in the maximal amplitude over the 7-day period of evaluation that peaked as early as days 3-4 (for example, C33A, HCT116) or later than days 6-7 (for example, HT29, Panc-1). There was an apparent trend where cell lines showing peak expression at early times were those with lower MOI 50 values, suggesting that efficient viral oncolysis may compromise the duration of NTR expression. The HUVE-12 endothelial cell line showed no detectable NTR expression, while weak and transient NTR expression could be detected for the SAEC cell line, consistent with respiratory epithelium as a preferred site for adenovirus replication. 78 The pattern of NTR and adenovirus fiber was synchronous and only observed 424 h post-ONYX-411 NTR infection as measured by western blot (Figure 3a ). In addition, both gene products were suppressed in samples treated with ara-C. NTR probe signal was found to coordinate with NTR immunoreactivity confirming the validity of SN 29884 as a fluorogenic probe for quantifying relative NTR expression (data not shown). For HCT116- 
WT cells infected with ONYX-411
WT , identical fiber protein expression kinetics were seen but no NTR co-expression was observed by western immunoblot (Figure 3b ) or detected by NTR probe (data not shown). Collectively these observations indicate that introduction of NTR transgene into the E3B region conferred an ability to deliver intracellular NTR activity with late gene expression kinetics that was conditional on viral replication.
In vitro potency and bystander efficiency of SN 27686 and CB 1954
Given the poor tolerance of humans to CB 1954, 56 there is a need to identify alternative NTR prodrugs to combine with NTR-armed VDEPT platforms. We have developed SN 27686, a 3,5-dinitrobenzamide bromomustard analog of CB 1954, in an attempt to provide an improved NTR prodrug for NTR VDEPT (Figure 4a ; see insert). The dinitrobenzamide mustard (DNBM) prodrug class are generally excellent substrates for E. coli NTR, 69, 70, 79 particularly the 3,5-dinitro isomer pattern for which structure-activity relationships will be reported elsewhere (Yang et al., unpublished data). We have determined that only the 3-nitro group of the alcohol prodrug SN 27686 is metabolized to the corresponding hydroxylamine species by NTR-expressing cells (data not shown) as recently demonstrated for reduction of the related DNBM PR-104 by endogenous reductases in hypoxic tumor cells, 75 an observation that is consistent with other analogs of this series 80 and reflects NTR active site constraints for the DNBM series. 81 Table 2 Table 2 as described in Methods. Under these stringent conditions of 1% NTR positive cells, SN 27686 provided a BEE of 4879% over three independent experiments, whereas the BEE value for CB 1954 was only 1378% under identical conditions.
Pharmacokinetics of SN 28343
While the DNBMs are superior NTR prodrugs in 3D cell cultures, like CB 1954 they have poor formulation properties for administration in vivo. 46, 63, 69 For example, SN 27686 has modest aqueous solubility (0.98 mM), although this is partly compensated by increased potency in vitro. To overcome this limitation we developed the pre-prodrug SN 28343, 77 a water-soluble (4200 mM) phosphate ester of SN 27686 (Figure 5a ). The MTD of SN 28343 as a single IP dose in CD-1 nude mice was found to be 750 mmol kg À1 (cf 200-240 mmol kg À1 for CB 1954 46, 63, 83 ). When SN 28343 was administered at 75% of MTD (562 mmol kg À1 ), both the phosphate and alcohol were identified in plasma by LC/MS (based on retention time, absorbance spectrum and mass spectrum compared with authentic standards; data not shown). The plasma pharmacokinetic profile showed rapid conversion of the phosphate SN 28343 (AUC 22 mmol h l
À1
) to the alcohol SN 27686 (AUC 39 mmol h l À1 ) which was the major species by 30 min (Figure 5b ).
NTR-dependent antitumor activity of CB 1954 and SN 28343
We have previously shown that WiDr colon tumor xenografts containing mixtures of NTR positive and negative cells provide a sensitive readout of bystander effects of DNBM prodrugs. 46 Using this methodology we WT in an identical manner demonstrated similar kinetics and amplitude of fiber expression but an absence of NTR co-expression.
Nitroreductase-armed oncolytic adenovirus DC Singleton et al Figure 4 Representative multicellular layer experiments comparing the nitroreductase (NTR) prodrugs (a) SN 27686 and (b) CB 1954. MCLs comprising 100% HCT116-WT cells or intimate mixtures of 99% HCT116-WT and 1% HCT116-NTR puro cells were grown for 3 days. These diffusion-limited structures were then exposed to various concentrations of CB1954 or SN27686 for 5 h under 5% CO 2 /95% O 2 before dissociation with trypsin/EDTA and plating (60 mm) from 10 2 to 10 5 cells to determine clonogenic survival in non-selective media or media containing puromycin (3 mM). On day 10, plates were stained with methylene blue and colonies 450 cells were counted. The survival of HCT116-WT and HCT116-NTR puro cells were calculated relative to untreated controls. compared the antitumor activity of CB 1954 and SN 28343 in vivo using xenografts grown from WiDr mixtures containing 0, 10 or 100% WiDr-NTR neo cells (Figure 6 ). Once established, tumor-bearing mice were treated with a single IP dose of either prodrug at MTD and the survival with tumors below end-point size was monitored. As expected, tumors lacking NTR-expressing cells displayed minimal sensitivity to either CB 1954 (IMS 3 days; P ¼ 0.017) or SN 28343 (IMS 8 days; Po0.001), whereas tumors composed of 100% WiDr-NTR neo cells were markedly sensitive to both agents (IMS 58 and 65 days, respectively; Po0.001). Xenografts composed of only a minority (10%) of NTR-expressing cells retained remarkable sensitivity to SN 28343 (IMS 62 days; Po0.001) being indistinguishable from 100% WiDr-NTR neo xenografts; a property that was not matched by CB 1954 treatment which, although significant (Po0.001), gave an IMS of only 11 days. These data confirmed SN 28343 as the preferred NTR prodrug for evaluation in combination with ONYX-411 NTR in vivo. 
ONYX-411 NTR replication in H1299 xenografts
Antitumor activity of ONYX-411
NTR in combination with SN 28343 H1299 tumor xenografts from the same cohort (tumor volume 388789 mm 3 ) were also challenged with ONYX-411 NTR (1 Â 10 8 PFU; IV) or vehicle and 10 days later the CRAd-treated mice were randomly assigned to receive either SN 28343 (0.15 mmol kg À1 per dose) or saline (q2dx12; IP). ONYX-411 NTR was unable to control these large tumors as a single agent (IMS 4 days; P ¼ 0.24), whereas subsequent administration of SN 28343 resulted in 5 of 8 (62.5%) complete regressions with no evidence of disease at 120 days (IMS 4100 days; Po0.001) (Figure 8 ). SN 28343 alone was not significantly active (IMS 9 days; P ¼ 0.14) indicating the combination of ONYX-411 NTR and SN 28343 was greater than additive. No significant differences in body weight loss nadir between groups was recorded (% pre-treatment (mean7s.e.m.); saline, À1.670.7%; ONYX-411 NTR ,À0.870.7%; SN 28343, À2.470.8%; ONYX-411 NTR þ SN 28343, À0.470.2%), indicating no toxicity interaction for the combined treatment relative to either agent alone. No treatment related deaths occurred although one animal (1/9) in the virus þ prodrug group was culled on ethical grounds due to tumor ulceration (day 28). We cannot exclude the possibility that this ulceration was treatment related. These data provide the first in vivo evidence of efficacy for an NTR 'armed' CRAd when combined with an NTR prodrug. 
Discussion
Virotherapy is an innovative approach to cancer therapy in which replication competent viruses are engineered to infect and lyse tumor cells selectively. Johnson et al. 19 developed the CRAd ONYX-411, to replicate conditionally in cells with a defective retinoblastoma pathway (490% of human cancers) 20, 24 ; a design that confers sufficient selectivity to enable single agent activity against human tumor xenografts following systemic IV administration. 19, 28 In the present study, we confirmed this activity using C33A xenografts (Figure 1b) . However, this cell line is relatively sensitive to ONYX-411 (Figure 1a) , as previously reported. 19 Thus, clinical utility of ONYX-411 as virotherapy is likely to require more intensive dosing regimes or combination with other agents, including potentially by 'arming' the virus with enzymes that activate prodrugs of cytotoxic chemotherapy.
We engineered ONYX-411 to express E. coli NTR by introducing the nfsB gene in the E3B region under the control of the native E3 viral transcriptional machinery. 71 The oncolytic potency of the resulting ONYX-411 NTR was found to be equivalent to WT both in vitro and in vivo (Figure 1 ), confirming that insertion of the nfsB open-reading frame did not compromise oncolytic activity. This genome location conferred replicationdependent late gene expression, as expected, 28, 71 which was demonstrated by delayed NTR presentation (424 h) following infection that was synchronous with adenoviral fiber protein expression and co-ablated by the viral replication inhibitor ara-C (Figure 3a) . Use of a novel fluorogenic NTR probe, SN 29884, demonstrated NTR expression was selective for tumor cells over primary proliferating human endothelial (HUVE-12) and epithelial (SAEC) cell cultures (Figure 2c ). The NTR probe also revealed that the amplitude and duration of NTR expression is heterogeneous across neoplastic cell lines exposed to ONYX-411 NTR . The expression profile is likely a reflection of both cellular susceptibility to initial infection, the kinetics of E2F-driven viral life cycle and eventual oncolysis, and importantly demonstrates that intracellular presentation of NTR is robust and durable despite the cytolytic nature of the viral vector. Given the dependence of NTR catalytic function on (intracellular) NAD(P)H availability, evidence of sustained NTR enzymatic activity post-infection (2 to 46 days) is an important prerequisite for CRAd-mediated prodrug metabolism. Collectively these data illustrate that recombinant ONYX-411 NTR is equivalent to its parent CRAd as a stand-alone therapeutic agent, while being concurrently capable of delivering sustained NTR expression to all neoplastic cells thus far tested.
Studies to date, using the first-generation NTR prodrug CB 1954 in combination with NTR-armed CRAds, have yet to provide clear evidence for a positive interaction in vivo using human tumor xenograft models in murine hosts. Chen et al. 84 reported that direct intratumor injection (2 Â 10 8 PFU per dose; qdx5) of the E1B-deleted CRAd CMV-NTR in SW480 xenografts provided a 36-day improvement in IMS that was extended by just 3 days on addition of CB 1954 (25 mg kg À1 per dose; IP, qdx4). Lukashev et al. 62 subsequently compared the efficacy of CMV-NTR with that of a Tcf-regulated CRAd harboring an L5-located NTR optimized for CB 1954 metabolism (Tcf-NTR). CRAd monotherapy (10 11 particles per mouse, IV) provided modest activity (IMS 2 and 12 days, respectively) and addition of CB 1954 again failed to enhance this effect (IMS over CRAd alone was 2 and 0 days, respectively). Given the apparent inability of CB 1954 to enhance CRAd-NTR activities in murine host xenografted human tumor models, despite a 55-fold higher plasma AUC of CB 1954 achievable in mice 63 relative to humans, 56 the need for a superior NTR prodrug is evident. We identified an alternate nitrogen mustard analog, SN 27686, for evaluation in vitro employing cell lines engineered to express NTR constitutively.
We observed that under conditions of low cell density CB 1954 was 2-to 4-fold more selective (WT/NTR IC 50 ratio) than SN 27686 against five NTR-positive cell lines (Table 1) , but this selectivity was reversed at tissue-like cell densities in HCT116 MCLs (WT/NTR C 10 ratio, Table 2 ). Across the NTR-expressing cell lines SN 27686 was 4-to 21-fold more dose potent than CB 1954 and at high cell-density this dose potency increased from 11.6-fold (by IC 50 ) to 42-fold (by C 10 ) with respect to HCT116-NTR puro (compare Tables 1 and 2 ). Moreover, the bystander killing efficiency was substantially superior for SN 27686 (48% of the maximum possible effect, with only 1% NTR positive cells in the MCLs) over CB 1954 (13%) ( Table 2 and Figure 4 ). This presumably reflects (Figure 5b ). Thus, SN 28343 is a two stage delivery system; systemic phosphatase-mediated conversion of the pre-prodrug (optimized for formulation) provides release of a prodrug that is subsequently metabolized by NTR to form alkylating metabolites. These redistribute efficiently eliciting a localized bystander effect.
WiDr colon xenografts grown by inoculating known proportions of NTR-expressing cells were used to compare the NTR-mediated bystander effects of the two prodrugs without the potentially complicating effects of interactions with viral oncolysis. Both prodrugs were equally efficacious against 100% WiDr-NTR neo xenografts with large survival gains that were the direct result of the presence of E. coli NTR as judged by the minimal response of the parental WiDr-WT xenografts. However, in tumors in which only a minority of cells were NTRpositive (a scenario more akin to the level of NTR expression that might be anticipated following exogenous delivery of NTR using viruses) SN 28343 relinquished none of its capacity to inhibit tumor growth whereas CB 1954 was barely active (Figure 6 ). This more efficient bystander effect in vivo is consistent with the greater bystander efficiency of SN 27686 over CB 1954 in MCLs ( Figure 4 and Table 2 ). The observation that SN 28343 retained such marked activity in the context of single administration against a mixed tumor cell model commended it for further evaluation in combination with ONYX-411 NTR . Next, we determined whether ONYX-411 NTR was able to infect and subsequently amplify in well-established H1299 xenografts following IV (systemic) administration. Following a modest single dose of 10 8 PFU (p10% of MTD), we observed NTR and adenovirus fiber expression in tissue homogenates of representative H1299 xenografts at days 14 and 30, whereas neither NTR nor fiber was detected in liver at any time ( Figure 7) . Similar robust and selective gene expressions following IV administration have been reported for ONYX-411 virus armed with E.coli CD in other tumor xenograft models (LnCaP, DU145 and HEP3B). 28 In order to relate the time-dependent amplification of ONYX-411 NTR to changes in tumor distribution, matched tumor tissue sections were examined for fiber immunoreactivity by fluorescent microscopy. In good agreement with the western blotting data, there was a substantial increase in fiber protein abundance and distribution at days 14 and 30, in contrast to day 6 when only foci of fiber positive regions were noted. We interpret these findings as indicting that substantial CRAd amplification and redistribution had occurred over time. Thus, our data confirm that ONYX-411 is a suitable systemic vehicle for tumor-specific delivery and expression of therapeutic transgenes, although these pilot studies of the kinetics and spatial distribution of NTR and fiber expression need to be expanded with larger series of tumors.
To determine whether tumor-specific expression of NTR could be translated into therapeutic gain, H1299 xenografts from the same cohort of virus-treated animals were randomized to receive SN 28343 or saline 10 days after virus administration, and virus-naı¨ve animals were similarly randomized. Only the combination of ONYX-411 NTR plus SN 28343 provided a marked survival advantage, with five of eight animals surviving long term with no evidence of additional body weight loss relative to single treatments, indicating therapeutic gain. Our interpretation of the data is that although ONYX-411 NTR infection of H1299 tumors is efficient, significant virusnaı¨ve regions persist, preventing effective tumor control and that addition of SN 28343 improves this outcome. Given the large volume of these tumors at the time of viral treatment, this result is particularly encouraging. The magnitude of the therapeutic action is perhaps surprising given the non-uniform macroregional virus distribution following single IV administration (Figure 7b) , and raises the prospect that prolonged prodrug administration may facilitate viral redistribution, although we cannot yet exclude the possibility that residual immunity of the nude mouse host might also contribute. These hypotheses are currently under investigation.
PR-104, a close analog of SN 28343 optimized as a hypoxia activated prodrug, entered clinical trials in 2006. 75 In recent studies, we have shown that the alcohol form of PR-104 is also an excellent substrate for NTR and displays marked activity in the WiDr mixed tumor model. Given the observations that hypoxia is an impediment to CRAd replication 85, 86 and a common feature of solid tumors, 87 the independent co-activation of PR-104 by hypoxia and NTR may be of significant therapeutic value. We are currently evaluating whether PR-104 provides efficacy similar to SN 28343 in combination with ONYX-411 NTR and thus whether it has potential clinical utility in this context. 
